The clinical characteristics and outcomes of asymptomatic patients with paroxysmal or persistent/permanent atrial fibrillation (AF) are largely unknown.
Detection and diagnosis of atrial fibrillation (AF) can be challenging in patients who are asymptomatic or minimally symptomatic, regardless of whether the AF is paroxysmal or persistent/permanent. 1 Undiagnosed asymptomatic AF is important and may lead to a first presentation with acute ischemic stroke or decompensated heart failure. 2 Several studies have compared the clinical characteristics and outcomes in patients with asymptomatic and symptomatic AF; however, the majority of patients in these studies had persistent or permanent AF and were reported from Western population cohorts. [3] [4] [5] There are limited data on differences in the clinical characteristics and outcomes of community-based asymptomatic patients with paroxysmal atrial fibrillation (PAF) and persistent/permanent AF, particularly from Asian cohorts.
The aim of the present study was to investigate the clinical profile and outcomes of patients with asymptomatic AF compared with symptomatic patients with PAF and sustained atrial fibrillation (SAF) (ie, persistent/permanent AF) from the Fushimi AF registry, a community-based prospective survey of Japanese patients with AF. [6] [7] [8] Methods
Study Cohort
The detailed study design, patient enrollment, definition of measurements, and subjects' baseline clinical characteristics in the Fushimi AF Registry have been described previously . 6 The inclusion criterion for the registry is the documentation of AF on a 12-lead ECG or Holter monitor at any time; there are no exclusion criteria. Patient enrollment was started in March 2011. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the ethics committees of the National Hospital Organization Kyoto Medical Center and Ijinkai Takeda General Hospital. See e-Appendix 1 for a list of the institutions participating in the registry.
Cohort Classification
The entire cohort was divided into two subgroups of AF, categorized as follows: (1) PAF, defined as self-terminating episodes lasting < 7 days; and (2) SAF, defined as either persistent (episodes lasting > 7 days that can be terminated either by pharmacological therapy or electric cardioversion) or permanent (AF that is accepted by the patient [and physician], for which rhythm control interventions are not pursued) AF. 9, 10 The patients were subsequently differentiated as being either asymptomatic or symptomatic at the time of enrollment based on their physicians' diagnosis and/or discretion. The symptoms of each patient were broadly described as one of the following: palpitations, orthopnea, fatigue, chest pain, and faintness. Patients were categorized as asymptomatic when the patient did not have any symptoms. The baseline characteristics and clinical outcomes of patients with asymptomatic and symptomatic AF were compared in the PAF and SAF groups.
Study End Points
The clinical end points in this analysis were the incidence of stroke/ systemic embolism, all-cause mortality, heart failure (HF) admission, and major bleeding episode during the follow-up period. These end points were also analyzed in the subgroups stratified according to oral anticoagulant (OAC) use at baseline. OACs included warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban. Stroke was defined as the sudden onset of a focal neurologic deficit in a location consistent with the territory of a major cerebral artery, and the diagnosis of ischemic or hemorrhagic stroke was confirmed by CT scanning or MRI. Systemic embolism was defined as an acute vascular occlusion of an extremity or organ. Major bleeding was defined as a reduction in the hemoglobin level of $ 2 g/dL, transfusion of $ 2 units of blood, or symptomatic bleeding in a critical area or organ. HF was defined according to clinical symptoms and signs, with a comprehensive examination to confirm the underlying cardiac disorder.
Statistical Analyses
Continuous variables are expressed as mean AE SD or median and interquartile range. Categorical variables are presented as numbers and percentages. Categorical variables were compared by using the c 2 test when appropriate; otherwise, the Fisher exact test was used. The Kaplan-Meier method was used to estimate the cumulative incidence of each clinical event. A multivariable analysis was conducted by using a logistic regression method to investigate the independent determinants of asymptomatic clinical status. The covariates chosen to be included in the model were male sex, coronary artery disease, chronic kidney disease (CKD) (persistent proteinuria or estimated glomerular filtration rate < 60 mL/min/1.73 m 2 ), 11 and components of the CHA 2 DS 2 -VASc risk score (congestive heart failure, hypertension, age $ 75 years, diabetes mellitus, history of stroke, vascular disease, age 65-74 years, and female sex). 12 A multivariable Cox proportional hazards model was used to calculate the hazard ratios (HRs) of asymptomatic status for major clinical events in the patients with PAF. Covariates chosen to be included in the model were age, body weight, history of stroke/systemic embolism, history of heart failure, hypertension, diabetes mellitus, coronary artery disease, peripheral artery disease, CKD, and history of major bleeding. Data were analyzed with the use of the online software, EZR (Easy R 32-bit version; http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/ statmed.html) for Windows. 13 A two-sided P value < .05 was considered statistically significant. CIs are reported as 95%.
Results
A total of 4,484 patients were enrolled by the end of December 2015. Of the 4,185 patients who were enrolled 1 year prior (by the end of December 2014), follow-up data (collected every year) were available for 3,749 patients (follow-up rate, 89.6%). Of these 3,749 patients, 1,971 patients (52.6%) were asymptomatic, and the remaining 1,778 patients (47.4%) were symptomatic; 1,837 patients (49%) had PAF and 1,912 patients (51%) had SAF. Furthermore, 689 patients (37.5%) and 1,282 patients (67.1%) were asymptomatic in the PAF and SAF groups, respectively. Median follow-up was 1,099 days (interquartile range, 479-1719 days).
Baseline Clinical Characteristics
Mean AE SD age and CHA 2 DS 2 -VASc score in the entire cohort were 73.6 AE 11 years and 3.37 AE 1.7, respectively. Asymptomatic patients were older and had a higher mean CHA 2 Baseline clinical characteristics of asymptomatic and symptomatic patients in both the PAF and SAF groups are summarized in Table 1 . In the PAF group, asymptomatic patients were more often male, older, and were more likely to have a history of stroke/ systemic embolism, CKD, and major bleeding. Both the mean CHADS 2 (congestive heart failure, hypertension, age $ 75 years, diabetes mellitus, and stroke/transient ischemic attack) and CHA 2 DS 2 -VASc scores were higher in asymptomatic patients. There was less use of class I antiarrhythmic drugs and b-blockers in the asymptomatic patients compared with symptomatic patients, whereas the OAC use was similar. In the SAF group, asymptomatic patients were often male and were more likely to have a history of stroke/systemic embolism, but the mean CHADS 2 and CHA 2 DS 2 -VASc scores were similar. There was a lower rate of class I antiarrhythmic drug, b-blocker, and diuretics use in asymptomatic patients. The use of OACs was also lower in asymptomatic patients than in symptomatic patients. A lower proportion of asymptomatic patients underwent invasive catheter ablation compared with symptomatic patients in both the PAF and SAF groups.
On multivariable logistic regression analysis, male sex, age ($ 75 years), CKD, history of stroke/systemic embolism, and major bleeding were significantly associated with asymptomatic status in the PAF group after adjusting for several covariates, including the components of the CHA 2 DS 2 -VASc score (Table 2 ). In the SAF group, the same covariates as in the PAF group, with the exception of age, were also significantly associated with asymptomatic status.
Clinical Outcomes
Major clinical events in the PAF or SAF group and in the entire cohort during the follow-up period are shown in Table 3 . Kaplan-Meier curves for the incidences of stroke/systemic embolism, all-cause mortality, HF admission, and major bleeding are shown in Figure 1 (PAF group) and Figure 2 (SAF group).
In the PAF group, all-cause mortality was significantly higher in asymptomatic patients compared with symptomatic patients (asymptomatic vs symptomatic, 7.25 vs 3.70 per 100 person-years; P < .01) ( Table 3) . The mortality between the asymptomatic PAF group and the entire SAF group was nonsignificantly different (7.25 vs 6.67 per 100 person-years; P ¼ .11). All other outcomes (stroke/systemic embolism, HF admission, and major bleeding) were nonsignificantly different between the asymptomatic and symptomatic patients in the PAF group.
On multivariable analysis, asymptomatic status was significantly associated with the higher mortality in patients with PAF after adjusting for potential confounders (HR, 1.71 [95% CI, 1.31-2.29]; P < .01) ( Table 4 (Table 3) .
Finally, we explored the risk factors of all-cause death in the patients with PAF, using multivariable logistic regression analysis. As shown in Table 5 , after adjusting for confounders, asymptomatic status was an independent risk factor for the incidence of all-cause death during the follow-up period in the PAF group (HR, 1.73 [95% CI, 1.29-2.33]; P < .01). 
Discussion
In this large community-based Asian cohort from Japan comparing characteristics and outcomes between patients with PAF and SAF in relation to symptomatic status, our principal findings are as follows: (1) asymptomatic patients had more comorbidities, with higher CHADS 2 and CHA 2 DS 2 -VASc scores, and a higher incidence of all-cause death compared with symptomatic patients in the PAF group, whereas these characteristics and outcomes were not seen in the SAF group; (2) independent determinants of asymptomatic presentation were male sex, age, CKD, and history of stroke/systemic embolism or major bleeding in the PAF group but not age in the SAF group; and (3) all-cause mortality was higher in asymptomatic patients compared with symptomatic patients in the PAF group, with asymptomatic clinical status being an independent risk factor for all-cause mortality.
Clinical Profile of Asymptomatic Patients
Asymptomatic AF is common in daily "real-world" clinical practice. [14] [15] [16] However, the relationship between patient characteristics and symptom presentation has not been consistent across studies and therefore remains controversial. In addition, these relationships have not been studied in community-based PAF and SAF groups, nor in Asian cohorts with AF.
In the present study, we reported distinct clinical characteristics of asymptomatic and symptomatic patients in the PAF group, rather than those in the SAF group. There were more co-morbidities, with higher CHADS 2 and CHA 2 DS 2 -VASc scores, in asymptomatic patients than in symptomatic patients in the PAF group, whereas these findings were similar in the SAF group. However, asymptomatic patients with PAF and SAF have similar risks of thromboembolism. The proportions of invasive and medical treatments were similar or less frequent in asymptomatic patients compared with symptomatic patients in both the PAF and SAF groups, indicating that the symptomatic status is likely to affect the physicians' decision regarding treatment strategy for patients with PAF and for those with SAF.
Male sex, CKD, and history of stroke/systemic embolism or major bleeding were significantly associated with asymptomatic status both in the PAF and SAF groups. The higher prevalence of asymptomatic status in male patients was consistent with previous reports. 17 Nonetheless, we recognize that CKD and previous stroke/systemic embolism or major bleeding may be related to physical disability and/or inactivity, which could make patients asymptomatic.
Clinical Outcomes of Asymptomatic Patients in the PAF and SAF Groups
In the present study, all-cause mortality was higher in asymptomatic than symptomatic patients but only in the PAF group. In a study by Boriani et al, 3, 15 asymptomatic patients were associated with more co-morbidities, higher CHA 2 DS 2 -VASc score, and higher mortality compared with symptomatic patients. The investigators therefore concluded that asymptomatic AF is not benign but is associated with a higher mortality risk, inconsistent with previous randomized clinical trials. 5, 18 Our data also found worse clinical outcomes in asymptomatic patients compared with the clinical outcomes of symptomatic patients in the PAF group but not in the SAF group. One possible reason for these distinct outcomes between the PAF and SAF subgroups may be due to the difficulty in detecting AF in patients with PAF compared with SAF. SAF can be easily detected with routine ECGs even in the absence of symptoms, but PAF would be less easily detected, especially if the patient was asymptomatic. Hence, optimal AF management would be delayed or inappropriate, including OAC treatment. Indeed, asymptomatic patients were older, with more Data are presented as incidence rates (per 100 person-years). P values for comparison between asymptomatic vs symptomatic using a log-rank test. HF ¼ heart failure. See Table 1 legend for expansion of other abbreviations. Data are presented as ORs and 95% CIs. See Table 1 legend for expansion of abbreviations.
chestjournal.org co-morbidities and higher CHA 2 DS 2 -VASc scores compared with symptomatic patients in the PAF group, perhaps because those patients were more likely to be undetected. In contrast, differences between asymptomatic and symptomatic patients were not observed in the SAF group, which suggests similarity of AF detection irrespective of patients' symptoms.
Studies have reported that patients with PAF have a lower rate of stroke/systemic embolism or mortality than those with SAF. 19, 20 However, the present study findings suggest that these outcomes were not applicable in terms of the asymptomatic clinical status. Our study highlights the worse outcomes of patients with asymptomatic PAF, which were comparable to those in patients with SAF, thus emphasizing the importance of early AF detection and holistic management in daily cardiology practice.
Several limitations should be acknowledged in interpreting the results of the present study. First, the results were derived from an observational study and describe associative, not causative, evidence. The present data were derived from an urban district in Japan, and therefore the results cannot be easily extrapolated to other rural areas, countries, or population-based registries. Second, because OAC data were collected only at the time of study entry, we could not examine the relationship between changes in OACs and clinical events. In addition, the type of antithrombotic drugs and doses were selected at the discretion of the attending physician. Third, we did not investigate the time in therapeutic range for patients receiving warfarin during follow-up or the adherence to OAC therapies. It is Data are presented as hazard ratios (HRs) and 95% CIs. HRs were adjusted by age, body weight, history of stroke/systemic embolism, history of HF, hypertension, diabetes mellitus, coronary artery disease, peripheral artery disease, chronic kidney disease, and history of major bleeding. See Table 1 and 3 legends for expansion of other abbreviations.
chestjournal.org therefore difficult to determine the influence of the quality of warfarin control and the adherence of OAC therapies on outcomes. Fourth, we were unable to assess AF burden, which might have affected the incidence of stroke/systemic embolism in patients with PAF. Fifth, the diagnosis of the type of AF, the determination of symptomatic/asymptomatic status, and the classification of symptoms were physician dependent at the time of enrollment, which may affect the clinical profiles and outcomes. Moreover, many asymptomatic patients (at enrollment) might have been previously symptomatic, but we did not have information on previous symptom status. Indeed, Boriani et al 3 reported the significant difference in the patient characteristics between fully asymptomatic patients and asymptomatic patients with previous symptoms. Sixth, there may be some selection bias for asymptomatic patients: the higher risk profiles might be related more to age than to symptom status, as being older usually represents a longer prior duration of AF, which may potentially lead to an asymptomatic status. Seventh, other minor symptoms that were not categorized into any of the five predefined symptom types may have been overlooked. We unfortunately have no data regarding the exercise capacity of asymptomatic patients, which might have a major impact on overall outcome. Finally, we cannot rule out the possibility of unmeasured or residual confounding, especially with age and co-morbidities, even after the multivariate analysis.
Despite these limitations, our study highlights the differences in the clinical profile and outcomes between asymptomatic and symptomatic patients in both the PAF and SAF cohorts. The present data also showed that asymptomatic patients with PAF may not receive adequate treatment, and thus better identification and management of such patients with PAF would be needed.
Conclusions
In this community-based, large prospective cohort of Japanese patients with AF, asymptomatic clinical status was associated with older age, male sex, more comorbidities with higher stroke risk profile, and a higher incidence of all-cause death in patients with PAF; these characteristics and outcomes were not seen in the SAF group. Data are presented as ORs and 95% CIs. See Table 1 legend for expansion of abbreviations.
